These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 24520399

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
    Kim J, Davies Z, Dunn C, Wine JJ, Milla C.
    J Cyst Fibros; 2018 Mar; 17(2):179-185. PubMed ID: 29279204
    [Abstract] [Full Text] [Related]

  • 5. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
    Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW, GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network.
    Am J Respir Crit Care Med; 2014 Jul 15; 190(2):175-84. PubMed ID: 24927234
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M, Krishan A, Patel S, Sinha IP, Southern KW.
    Cochrane Database Syst Rev; 2019 Jan 07; 1(1):CD009841. PubMed ID: 30616300
    [Abstract] [Full Text] [Related]

  • 10. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS.
    Ann Pharmacother; 2012 Jan 07; 46(7-8):1065-75. PubMed ID: 22739718
    [Abstract] [Full Text] [Related]

  • 11. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, VX 08-770-104 Study Group.
    Chest; 2012 Sep 07; 142(3):718-724. PubMed ID: 22383668
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
    Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS, VX08-770-102 Study Group.
    N Engl J Med; 2011 Nov 03; 365(18):1663-72. PubMed ID: 22047557
    [Abstract] [Full Text] [Related]

  • 14. Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults.
    Kim J, Farahmand M, Dunn C, Milla CE, Horii RI, Thomas EAC, Moss RB, Wine JJ.
    Sci Rep; 2018 Nov 02; 8(1):16233. PubMed ID: 30389955
    [Abstract] [Full Text] [Related]

  • 15. In vivo readout of CFTR function: ratiometric measurement of CFTR-dependent secretion by individual, identifiable human sweat glands.
    Wine JJ, Char JE, Chen J, Cho HJ, Dunn C, Frisbee E, Joo NS, Milla C, Modlin SE, Park IH, Thomas EA, Tran KV, Verma R, Wolfe MH.
    PLoS One; 2013 Nov 02; 8(10):e77114. PubMed ID: 24204751
    [Abstract] [Full Text] [Related]

  • 16. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.
    Cochrane Database Syst Rev; 2015 Mar 26; (3):CD009841. PubMed ID: 25811419
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY, Zhang S, Lazrak A, Grayson JW, Peña Garcia JA, Skinner DF, Lim DJ, Mackey C, Banks C, Matalon S, Woodworth BA.
    Int Forum Allergy Rhinol; 2019 Jan 26; 9(1):100-105. PubMed ID: 30152192
    [Abstract] [Full Text] [Related]

  • 19. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, Rowe SM, Sagel SD.
    Ann Am Thorac Soc; 2020 Feb 26; 17(2):212-220. PubMed ID: 31604026
    [Abstract] [Full Text] [Related]

  • 20. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T - a case report.
    Welsner M, Straßburg S, Taube C, Sutharsan S.
    BMC Pulm Med; 2019 Apr 11; 19(1):76. PubMed ID: 30975115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.